PriceTargets.com logo

CARGO Therapeutics - CRGX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $29.67
  • Forecasted Upside: 41.54%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$20.96 As of 05/2/2024 06:13 PM ET
▲ +0.42 (2.04%)

This chart shows the closing price for CRGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New CARGO Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRGX

Analyst Price Target is $29.67
▲ +41.54% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for CARGO Therapeutics in the last 3 months. The average price target is $29.67, with a high forecast of $34.00 and a low forecast of $23.00. The average price target represents a 41.54% upside from the last price of $20.96.

This chart shows the closing price for CRGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in CARGO Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/8/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/6/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/4/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/2/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/2/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/2/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/22/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$28.00 ➝ $32.00Low
12/5/2023Truist FinancialInitiated CoverageBuy$34.00Low
12/5/2023Jefferies Financial GroupInitiated CoverageBuy$28.00Low
12/5/2023JPMorgan Chase & Co.Initiated CoverageOverweight$23.00Low
12/5/2023TD CowenInitiated CoverageOutperformLow
(Data available from 5/2/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
2/2/2024
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/3/2024
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/2/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/2/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

CARGO Therapeutics logo
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Read More

Today's Range

Now: $20.96
Low: $19.84
High: $21.01

50 Day Range

MA: $23.39
Low: $18.28
High: $32.23

52 Week Range

Now: $20.96
Low: $13.14
High: $33.92

Volume

117,015 shs

Average Volume

266,304 shs

Market Capitalization

$825.17 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of CARGO Therapeutics?

The following equities research analysts have issued stock ratings on CARGO Therapeutics in the last year: Jefferies Financial Group Inc., JPMorgan Chase & Co., TD Cowen, and Truist Financial Co..
View the latest analyst ratings for CRGX.

What is the current price target for CARGO Therapeutics?

3 Wall Street analysts have set twelve-month price targets for CARGO Therapeutics in the last year. Their average twelve-month price target is $29.67, suggesting a possible upside of 41.5%. Truist Financial Co. has the highest price target set, predicting CRGX will reach $34.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $23.00 for CARGO Therapeutics in the next year.
View the latest price targets for CRGX.

What is the current consensus analyst rating for CARGO Therapeutics?

CARGO Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRGX will outperform the market and that investors should add to their positions of CARGO Therapeutics.
View the latest ratings for CRGX.

What other companies compete with CARGO Therapeutics?

Other companies that are similar to CARGO Therapeutics include Mesoblast, Kyverna Therapeutics, REGENXBIO, Relay Therapeutics and ProKidney. Learn More about companies similar to CARGO Therapeutics.

How do I contact CARGO Therapeutics' investor relations team?

CARGO Therapeutics' physical mailing address is 1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA 94403, United States. The company's listed phone number is 650-379-6143 and its investor relations email address is [email protected]. The official website for CARGO Therapeutics is cargo-tx.com. Learn More about contacing CARGO Therapeutics investor relations.